Alpha Club's TRT estrogen advice: mostly right, key details wrong

What did @alphaclubsupps actually say?

The creator's core argument is straightforward: if your estrogen is running high on TRT, the first fix should be adjusting your protocol, not reaching for an aromatase inhibitor (AI) or adding compounds like masteron. Specifically, he recommends either reducing your total dose or splitting it into more frequent injections, then rechecking bloodwork before making any other changes.

He also makes a secondary claim worth noting: that long-term use of extra compounds like AIs or masteron "is not very healthy" for someone on TRT for life. That's a position, not a wild claim, and it's one many endocrinologists would broadly agree with.

To his credit, he doesn't recommend a specific dose, doesn't promise estrogen will normalize, and explicitly says to recheck labs. That's more medically responsible than a lot of what circulates in TRT spaces on social media.

Does the science back this up?

Yes, mostly. The pharmacokinetics here are solid. Testosterone cypionate and enanthate have long half-lives, and large infrequent injections create supraphysiologic peaks that drive more aromatization. More frequent, smaller doses smooth that curve out.

Shoskes et al. (2016, Translational Andrology and Urology) laid out how injection frequency affects hormone stability. More frequent dosing reduces peak-to-trough fluctuation, which correlates with more stable estradiol levels. This isn't controversial in clinical endocrinology.

The aromatization piece is also backed. Testosterone converts to estradiol via the aromatase enzyme, and higher peak testosterone concentrations drive more conversion. Reducing the dose or flattening the curve logically reduces aromatase substrate. Dobs et al. (1999, Journal of Clinical Endocrinology and Metabolism) confirmed that estradiol levels track closely with total testosterone dose in hypogonadal men on replacement therapy.

Where it gets more nuanced is his blanket skepticism of AIs. That's a defensible clinical preference, but it's not a universal rule.

What did they get wrong (or right)?

He got the core pharmacology right, and that deserves credit. But the framing around AIs and masteron needs pushback.

Calling masteron a compound that "masks the effect of E2" is oversimplified. Masteron (drostanolone) has weak aromatase inhibitor properties and competes at androgen receptors. Calling it purely a masking agent undersells its actual mechanism and overstates its relevance to clinical TRT. More importantly, masteron is not a standard or accepted tool in therapeutic TRT. Recommending it even implicitly in a TRT context, not a performance context, is a red flag.

His skepticism of AIs as a long-term strategy has real clinical backing. Anastrozole and exemestane suppress estradiol, but estradiol in men is not simply an antagonist. Carani et al. (1997, New England Journal of Medicine) showed estradiol plays a role in bone density, libido, and cardiovascular function in men. Chronically suppressing it with an AI creates its own problems. So his instinct to avoid AIs long-term is grounded, even if his reasoning is vague.

What he doesn't address: some men aromatize heavily regardless of dose or frequency due to body composition, genetics, or comorbidities. For those patients, protocol adjustment alone may not be sufficient, and that's a conversation to have with a prescribing physician, not a TikTok comment section.

What should you actually know?

Estrogen management on TRT is more individual than any single TikTok protocol can capture. Here is what the evidence actually supports.

• More frequent injections do reduce estradiol peaks in most men. This is pharmacokinetics, not bro-science.
• AIs carry real risks when used long-term, including bone loss and lipid changes. They are not a casual addition.
• Estradiol in the 20-40 pg/mL range is generally considered appropriate for men on TRT. Tanking it to single digits causes problems of its own.
• Masteron is not a clinical TRT medication. Its appearance in a TRT conversation is a signal you are in performance enhancement territory, not therapeutic replacement territory.
• Bloodwork is non-negotiable. Adjusting a protocol without labs is guessing. The creator was right to say "redo your bloods after a time."

If your estrogen is elevated on TRT, a legitimate first step is reviewing dose and frequency with your prescribing physician. That is not controversial. But if protocol adjustments do not resolve the issue, there are clinical options that should be discussed with a licensed provider, not sourced from supplement brand TikTok accounts.